tradingkey.logo
๎™๊ฒ€์ƒ‰
์‹œ์žฅ
๊ด€์‹ฌ ๋ชฉ๋ก
๋‰ด์Šค
๋ถ„์„
๋„๊ตฌ
์ข…๋ชฉ ์Šคํฌ๋ฆฌ๋„ˆ
๎™ผ
๎˜
English
็นไฝ“ไธญๆ–‡
เน„เธ—เธข
Tiแบฟng viแป‡t
็ฎ€ไฝ“ไธญๆ–‡
Espaรฑol
Portuguรชs
Deutsch
ํ•œ๊ตญ์–ด
๎˜ณ
ๆ—ฅๆœฌ่ชž
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™
๎˜

Atossa Therapeutics Inc

ATOS
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
2.250USD
+0.030+1.35%
์ข…๊ฐ€ย 09-18 16:00๏ผˆET๏ผ‰
22.50M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Atossa Therapeutics Inc

2.250
+0.030+1.35%
๊ฐœ์š”
๋‰ด์Šค & ๋ถ„์„
๊ธˆ์œต
์ฃผ์‹ ์ ์ˆ˜
๊ธฐ์ˆ 
์˜ˆ์ƒ
์†Œ์œ ๊ถŒ
๋ฐฐ๋‹น๊ธˆ
ํ”„๋กœํ•„
ํ† ๋ก 
์žฌ๋ฌด ์š”์•ฝ์†์ต๊ณ„์‚ฐ์„œ์žฌ๋ฌด์ƒํƒœํ‘œํ˜„๊ธˆ ํ๋ฆ„ํ‘œ์žฌ๋ฌด์ œํ‘œ๊ธฐ์—… ๊ฐ€์น˜ ํ‰๊ฐ€์œ„ํ—˜ ์š”์†Œ

๊ฐœ์š”

๋‰ด์Šค & ๋ถ„์„

๊ธˆ์œต

์ฃผ์‹ ์ ์ˆ˜

๊ธฐ์ˆ 

์˜ˆ์ƒ

์†Œ์œ ๊ถŒ

๋ฐฐ๋‹น๊ธˆ

ํ”„๋กœํ•„

ํ† ๋ก 

์žฌ๋ฌด ์š”์•ฝ์†์ต๊ณ„์‚ฐ์„œ์žฌ๋ฌด์ƒํƒœํ‘œํ˜„๊ธˆ ํ๋ฆ„ํ‘œ์žฌ๋ฌด์ œํ‘œ๊ธฐ์—… ๊ฐ€์น˜ ํ‰๊ฐ€์œ„ํ—˜ ์š”์†Œ

ATOS ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Atossa Therapeutics Inc์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋Š ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ•ต์‹ฌ ์žฌ๋ฌด ๋น„์œจ

์‹œ๊ฐ€์ด์•ก
22.50M
๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.00
P/E TTM
-0.04
์ฃผ๋‹น์ˆœ์ด์ต
-60.90
์ˆ˜์ต
--
์ˆœ์ด์ต
-25.50M
ROE
-78.58%
ROA
-69.26%

Atossa Therapeutics Inc ์‹ค์  ๋ฐœํ‘œ์ผ๎˜

์ตœ์‹  ์ถœ์‹œ
Aug 7, 2026
EPS / ์˜ˆ์ƒ
-0.95/-1.03
์ˆ˜์ต / ์˜ˆ์ƒ
--/0.00

์žฌ๋ฌด์ œํ‘œ ์š”์•ฝ

๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
์žฌ๋ฌด ์ง€ํ‘œ
EPS
2.56%-0.95
-42.55%-1.11
-68.91%-1.27
-17.07%-1.01
-35.54%-0.98
-10.90%-0.78
-1114.98%-0.75
-1641.11%-0.86
-829.60%-0.72
-1318.35%-0.70
-4.61%-0.06
---0.05
---0.08
---0.05
---0.06
---0.15
----
----
----
----
์ˆœ์ด์ต
-0.81%-8.49M
-42.74%-9.59M
-72.32%-10.94M
-20.22%-8.69M
-39.25%-8.42M
-14.29%-6.72M
18.15%-6.35M
-16.07%-7.23M
38.46%-6.05M
6.42%-5.88M
-3.51%-7.75M
22.24%-6.23M
-47.33%-9.83M
-31.24%-6.28M
-55.04%-7.49M
-54.14%-8.01M
5.22%-6.67M
-35.27%-4.79M
59.69%-4.83M
-48.87%-5.20M
์†์ต๊ณ„์‚ฐ์„œ๎˜
์˜์—… ์ด์ต
3.83%-8.69M
-33.13%-9.87M
-59.92%-11.44M
-44.89%-9.25M
-27.23%-9.04M
-6.22%-7.41M
20.71%-7.15M
14.50%-6.38M
8.83%-7.11M
1.66%-6.98M
-10.83%-9.02M
8.98%-7.47M
-18.17%-7.79M
-49.53%-7.10M
-68.56%-8.14M
-59.05%-8.21M
5.84%-6.59M
-34.45%-4.75M
-14.25%-4.83M
-47.02%-5.16M
์ˆœ์ด์ต
-0.81%-8.49M
-42.74%-9.59M
-72.32%-10.94M
-20.22%-8.69M
-39.25%-8.42M
-14.29%-6.72M
18.15%-6.35M
-16.07%-7.23M
38.46%-6.05M
6.42%-5.88M
-3.51%-7.75M
22.24%-6.23M
-47.33%-9.83M
-31.24%-6.28M
-55.04%-7.49M
-54.14%-8.01M
5.22%-6.67M
-35.27%-4.79M
59.69%-4.83M
-48.87%-5.20M
์žฌ๋ฌด์ƒํƒœํ‘œ๎˜
์œ ๋™์ž์‚ฐ
-50.40%31.01M
-46.66%36.67M
-38.73%45.62M
-27.79%55.68M
-23.50%62.52M
-21.03%68.74M
-19.26%74.46M
-21.03%77.11M
-22.91%81.72M
-21.48%87.06M
-21.98%92.22M
-20.87%97.65M
-20.55%106.00M
-18.98%110.87M
-16.31%118.20M
-13.70%123.39M
-8.51%133.42M
-2.97%136.85M
230.23%141.24M
1163.32%142.99M
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
-20.07%5.45M
37.46%7.46M
66.20%8.26M
41.91%8.22M
19.73%6.82M
1.82%5.42M
-5.14%4.97M
68.29%5.80M
63.77%5.70M
80.98%5.33M
-5.96%5.24M
20.08%3.44M
-8.28%3.48M
26.79%2.94M
78.12%5.57M
71.14%2.87M
111.12%3.79M
68.36%2.32M
-80.05%3.13M
7.06%1.68M
์ด ์ž์‚ฐ
-49.96%32.28M
-46.37%37.94M
-37.72%47.61M
-27.01%58.01M
-24.86%64.52M
-22.33%70.75M
-20.58%76.44M
-21.85%79.48M
-20.76%85.86M
-21.61%91.09M
-22.08%96.25M
-19.75%101.69M
-19.17%108.36M
-15.48%116.20M
-12.55%123.53M
-11.40%126.72M
-8.10%134.05M
-2.55%137.48M
229.75%141.26M
1150.46%143.02M
๋ถ€์ฑ„ ์ด๊ณ„
-20.07%5.45M
37.46%7.46M
66.20%8.26M
41.91%8.22M
19.73%6.82M
1.82%5.42M
-5.14%4.97M
68.29%5.80M
63.77%5.70M
80.98%5.33M
-5.96%5.24M
20.08%3.44M
-8.28%3.48M
26.79%2.94M
78.12%5.57M
71.14%2.87M
111.12%3.79M
68.36%2.32M
-80.05%3.13M
6.97%1.68M
์ž๋ณธ ์ด๊ณ„
-53.50%26.83M
-53.33%30.49M
-44.94%39.35M
-32.43%49.79M
-28.03%57.70M
-23.83%65.32M
-21.47%71.48M
-25.01%73.68M
-23.57%80.16M
-24.28%85.76M
-22.84%91.02M
-20.67%98.25M
-19.48%104.88M
-16.20%113.26M
-14.60%117.96M
-12.38%123.86M
-9.59%130.26M
-3.25%135.16M
408.45%138.14M
1331.94%141.35M
ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๎˜
์ˆœ์˜์—…์ด์ต
-32.86%-9.64M
-60.78%-9.58M
-49.47%-10.54M
-26.42%-6.00M
-60.21%-7.26M
-26.84%-5.96M
-26.57%-7.05M
-22.33%-4.75M
-1.48%-4.53M
33.10%-4.70M
-23.17%-5.57M
28.23%-3.88M
24.95%-4.46M
-43.95%-7.02M
-23.40%-4.52M
-76.71%-5.41M
-11.48%-5.95M
-10.64%-4.88M
-6.78%-3.67M
-14.31%-3.06M
์ˆœํˆฌ์ž
--0.00
100.00%0.00
---7.00K
30.00%-7.00K
100.00%0.00
-50.00%-9.00K
--0.00
-900.00%-10.00K
76.92%-3.00K
---6.00K
100.00%0.00
99.96%-1.00K
---13.00K
100.00%0.00
-507170.71%-2.01M
-28699.49%-2.71M
--0.00
---13.00K
--396.00
-240.81%-9.40K
์ˆœ์žฌ๋ฌดํ™œ๋™
--4.02M
--0.00
-100.00%0.00
--0.00
-100.00%0.00
-100.00%0.00
--3.37M
100.00%0.00
--100.00K
--204.00K
--0.00
---1.48M
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%718.00
-84.30%678.93K

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Atossa Therapeutics Inc์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 45.62M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -38.73์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Atossa Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ 47.61M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -37.72์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Atossa Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” 8.26M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 66.20์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Atossa Therapeutics Inc์˜ ์ด์ž๋ณธ์€ 39.35M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -44.94์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Atossa Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ -37.14M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -34.47์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Atossa Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” -23.00K์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -21.05์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ -60.57์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -1892.55์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ -34.77M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -36.33์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ -62.74์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -99.88์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ -56.06์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -89.79์ž…๋‹ˆ๋‹ค.

Atossa Therapeutics Inc์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Atossa Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ -37.14M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -34.47์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ 
์ด์šฉ ์•ฝ๊ด€
๊ฐœ์ธ์ •๋ณด ์ฒ˜๋ฆฌ๋ฐฉ์นจ
์ฟ ํ‚ค ์ •์ฑ